07:00 , May 8, 2000 |  BC Week In Review  |  Clinical News

Alamast pemirolast ophthalmic solution: Marketed

Santen said that in parallel group trials involving 400 patients for up to 17 weeks during ragweed season, Alamast significantly prevented ocular itching compared to placebo. In one study, Alamast significantly reduced ocular redness versus...
07:00 , Oct 4, 1999 |  BC Week In Review  |  Clinical News

Alamast pemirolast ophthalmic solution regulatory update

The FDA granted marketing approval for Santen's Alamast mast cell stabilizing solution, which inhibits the antigen-induced release of inflammatory mediators involved in the allergic process, to prevent itchy eyes due to allergic conjunctivitis. Santen Inc....